Harrow Health Inc

Viatris reported second-quarter revenue of $3.8 billion, up 3.5% operationally, and raised its full-year 2026 guidance across all key metrics. Adjusted EBITDA rose 8% operationally to $1.2 billion, and adjusted EPS grew 9% to $0.69, driven by 16% operational growth in Greater China and strength in North American complex generics. The company now expects 2026 revenue of $14.55 billion to $14.95 billion, adjusted EBITDA of $4.3 billion to $4.5 billion, and adjusted EPS of $2.45 to $2.59, with midpoints raised for all three. Viatris also announced FDA approval of its Gwyn Lo contraceptive patch, a $30 million upfront deal to sell Tyrvaya rights to Harrow, and completion of its Biocon stake sale for $380 million, while warning that Nashik facility disruptions could cut second-half revenue by $100 million to $150 million.

Harrow reported second-quarter revenue of $70.7 million, an 11% increase year over year, driven by stronger demand for VEVYE, IHEEZO and specialty products. The company reiterated its full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million. Management expects second-half growth from improved VEVYE pricing and expanded commercial coverage, IHEEZO's 25% net price increase, BYOOVIZ and the relaunch of VERKAZIA. Harrow plans to acquire global rights to TYRVAYA for $30 million in cash, with more than $30 million of revenue expected in 2027 if the deal closes. The company also advanced pipeline programs G-MELT and YOCHIL, targeting future FDA submissions.

Samsung Bioepis has relaunched its interchangeable ophthalmology biosimilar BYOOVIZ in the United States in partnership with Harrow. BYOOVIZ, a biosimilar referencing Lucentis, was the first ophthalmology biosimilar to gain FDA approval in September 2021 and received interchangeability designation in October 2023. Harrow assumed commercialization responsibility for BYOOVIZ and another interchangeable biosimilar, OPUVIZ, after Biogen returned commercial rights to Samsung Bioepis at the end of 2025. Samsung Bioepis will continue to handle development, regulatory registration, and manufacturing, while Harrow leads US commercialization. The relaunch aims to expand patient access to a quality-proven, cost-effective treatment for wet age-related macular degeneration and other retinal conditions.